JPH02113885A - Preparation of epithelial cell cultured in multiple layers - Google Patents
Preparation of epithelial cell cultured in multiple layersInfo
- Publication number
- JPH02113885A JPH02113885A JP63266579A JP26657988A JPH02113885A JP H02113885 A JPH02113885 A JP H02113885A JP 63266579 A JP63266579 A JP 63266579A JP 26657988 A JP26657988 A JP 26657988A JP H02113885 A JPH02113885 A JP H02113885A
- Authority
- JP
- Japan
- Prior art keywords
- cell
- culture
- medium
- epithelial cells
- cultured
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002919 epithelial cell Anatomy 0.000 title claims abstract description 38
- 210000004027 cell Anatomy 0.000 claims abstract description 74
- 229920000249 biocompatible polymer Polymers 0.000 claims abstract description 13
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000003255 drug test Methods 0.000 claims abstract description 11
- 238000012258 culturing Methods 0.000 claims abstract description 9
- 239000000284 extract Substances 0.000 claims abstract description 9
- 241000283690 Bos taurus Species 0.000 claims abstract description 7
- 102000004877 Insulin Human genes 0.000 claims abstract description 6
- 108090001061 Insulin Proteins 0.000 claims abstract description 6
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 6
- 229940125396 insulin Drugs 0.000 claims abstract description 6
- 101800003838 Epidermal growth factor Proteins 0.000 claims abstract description 4
- 229940116977 epidermal growth factor Drugs 0.000 claims abstract description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims abstract description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract 2
- 206010062767 Hypophysitis Diseases 0.000 claims abstract 2
- 210000003635 pituitary gland Anatomy 0.000 claims abstract 2
- 239000012528 membrane Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 abstract description 5
- 102000008186 Collagen Human genes 0.000 abstract description 5
- 229920001436 collagen Polymers 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 4
- 241000282414 Homo sapiens Species 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 2
- 239000002609 medium Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 22
- 229940079593 drug Drugs 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 239000010410 layer Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 10
- 210000004748 cultured cell Anatomy 0.000 description 8
- 230000007794 irritation Effects 0.000 description 8
- 230000035699 permeability Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 238000010171 animal model Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 231100000820 toxicity test Toxicity 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 241000237536 Mytilus edulis Species 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000012817 gel-diffusion technique Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000009760 electrical discharge machining Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- -1 polyethylene terephthalate Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
【発明の詳細な説明】
産業上の利用分野
この発明は、薬物の毒性試験、刺激性試験、浸透性試験
および代謝性試験等の薬物試験を生体外で行なうのに好
適な多層培養上皮細胞の製法に関する。DETAILED DESCRIPTION OF THE INVENTION Field of Industrial Application This invention relates to the use of multilayer cultured epithelial cells suitable for in vitro drug tests such as drug toxicity tests, irritation tests, permeability tests, and metabolic tests. Regarding the manufacturing method.
従来の技術
従来から薬物の毒性試験、刺激性試験、浸透性試験およ
び代謝性試験等においては、特定の病原菌を保持しない
ように管理された環境下で飼育されるS P E(sp
eeific pathology free)動物ま
たは管理された交配下で得られる系統や遺伝特性の明確
な動物等の実験動物が生きして利用されている。BACKGROUND OF THE INVENTION Conventionally, in drug toxicity tests, irritation tests, permeability tests, metabolic tests, etc., SPE (sp.
Experimental animals such as animals with clear lines and genetic characteristics obtained through controlled breeding are used live.
例えば、毒性試験や刺激性試験においては、薬物を種々
の手段によって動物体内へ投与してその生体的変化を追
跡し、また浸透性試験においては、動物の皮膚表面に塗
布して経時的に採取する血液中の薬物や代謝物の濃度を
調べるか、または動物の腹部や背面等の特性の部位から
採取する皮膚片に対する薬物の浸透性を種々の手段で調
べる等の方法が採用されている。For example, in toxicity and irritation tests, drugs are administered into the animal body by various means and biological changes are tracked, and in permeability tests, drugs are applied to the animal's skin surface and collected over time. Various methods have been adopted, such as examining the concentration of drugs and metabolites in the blood of animals, or examining the permeability of drugs to skin strips taken from specific areas such as the abdomen or back of animals.
しかしながら、実験動物を用いる試験には相当な費用と
労力を必要とするばかりでなく、最近特に活発化してい
る動物愛護運動の影響等もあって入手源や使用が制限さ
れ、また動物個体間でデ−夕のばらつきが大きい等の問
題がある。However, testing using laboratory animals not only requires considerable cost and labor, but also due to the influence of the animal protection movement that has become particularly active recently, there are restrictions on the source and use of these animals, and There are problems such as large variations in data.
このため、実験動物を用いる試験法に代替する方法とし
て培養上皮細胞を用いる生体外試験法が利用されるよう
になっている。For this reason, in vitro testing methods using cultured epithelial cells have come to be used as an alternative to testing methods using experimental animals.
例えば、初代もしくは株細胞を培養皿上において培地と
薬物の共存下において培養させ、該培養皿上に付着増殖
する細胞の数や形態等を種々の手段で評価することによ
って薬物の毒性や刺激性等を試験する方法、細胞層上部
もしくはゲルの内部から培地と薬物を供給し、て細胞培
養を行ない、増殖する細胞の数や形態等を評価すること
によって薬物の毒性や刺激性等を試験する寒天ゲル拡散
法もしくはコラーゲンゲル拡散法が知られている。For example, primary cells or cell lines are cultured on a culture dish in the coexistence of a medium and a drug, and the number and morphology of cells that adhere to and proliferate on the culture dish are evaluated by various means to determine the toxicity and irritation of the drug. The toxicity and irritation of the drug are tested by supplying the medium and drug from the top of the cell layer or from inside the gel, culturing cells, and evaluating the number and morphology of proliferating cells. Agar gel diffusion method or collagen gel diffusion method is known.
しかしながら、これらの方法によ−)で得られる結果は
生体内での状態、即ち、被験細胞は三次元的溝戊をとり
、該細胞、智の上部から薬物が供給され、下部から栄養
分が供給されるという状態を正確に反映するものではな
い。However, the results obtained with these methods are based on the in vivo state, i.e., the test cells have a three-dimensional groove, and the drug is supplied from the upper part of the cell, and nutrients are supplied from the lower part. It does not accurately reflect the situation.
また、別の生体外試験法として、培養ウェル内に膜フィ
ルター付培養セルを配設し、両者の間隙内に培地、例え
ばM E M、 Medium l 99、McCoy
s 5 A、 MediumまたはHam F l 2
等に血清を約10〜20%添加した培地を入れ、培養セ
ルの膜フィルター上で培養して得られる培養上皮細胞に
対する薬物の影響を調べる方法が知られている。しかし
ながら、この方法の場合は、被験細胞の培養において、
細胞の接種直後から細胞の増殖と分化が起こり、均一な
細胞層が形成されるまでに細胞分裂が停止するためにピ
ンホールのない均一な三次元的な培養細胞が得られない
という難点がある。ピンホールのある不均一な単層培養
上皮細胞を使用する生体外薬物試験法の場合には、生体
内での状態を正確に友映する結果が得られないばかりで
なく、毒性試験や刺激性試験においてはデータがばらつ
き、また、浸透性試験や代謝性試験を行なうことは不可
能である。In addition, as another in vitro test method, a culture cell with a membrane filter is placed in a culture well, and a medium, such as MEM, Medium 99, McCoy, is placed in the gap between the two.
s 5 A, Medium or Ham Fl 2
A known method is to investigate the effect of a drug on cultured epithelial cells obtained by adding a medium supplemented with about 10 to 20% serum to a cell culture cell and culturing it on a membrane filter of a culture cell. However, in the case of this method, in culturing the test cells,
Cell proliferation and differentiation occur immediately after cell inoculation, and cell division stops before a uniform cell layer is formed, making it difficult to obtain uniform three-dimensional cultured cells without pinholes. . In vitro drug testing methods that use heterogeneous monolayer cultured epithelial cells with pinholes not only do not provide results that accurately reflect in vivo conditions, but also are difficult to test for toxicity and irritation. Test data vary, and it is not possible to perform permeability or metabolic tests.
発明が解決しようとする課題
この発明は、従来の薬物の生体外試験法の上記諸問題を
解決し、実験動物を使用する薬物の生体内試験法に十分
に代替し得る生体外薬物試験法に使用するのに好適な培
養上皮細胞を提供するためになされたものである。Problems to be Solved by the Invention The present invention solves the above-mentioned problems of conventional in vitro drug testing methods, and provides an in vitro drug testing method that can fully replace in vivo drug testing methods that use laboratory animals. This was done to provide cultured epithelial cells suitable for use.
課題を解決するための手段
即ち本発明は、培養セルの底部に設けた生体親和性高分
子膜上に上皮細胞を接種し、該上皮細胞をMCDB l
53、インスリン、表皮細胞成長因子、ハイドロコー
チゾンおよびウシ下垂体抽出物を含有する培地を用いて
培養することを特徴とする多層培養上皮細胞の製法に関
する。Means for solving the problem, that is, the present invention, is to inoculate epithelial cells onto a biocompatible polymer membrane provided at the bottom of a culture cell, and to inoculate the epithelial cells with MCDB l.
53, relates to a method for producing multilayer cultured epithelial cells characterized by culturing them using a medium containing insulin, epidermal cell growth factor, hydrocortisone, and bovine pituitary extract.
以下、本発明を添付図に基づいて説明する。Hereinafter, the present invention will be explained based on the accompanying drawings.
第1因は本発明を実施するのに好適な培養セルの一態様
を示す平面図、第2図は該セルの下面図、第3図は該セ
ルの背可図、第4図は該セルの正面図および第5図は第
1図〜第4図に示す培養セルをマルチ培養ウェルプレー
トに懸垂して上皮細胞を培養する状態を示す部り的断面
図である。The first factor is a plan view showing one embodiment of a culture cell suitable for carrying out the present invention, FIG. 2 is a bottom view of the cell, FIG. 3 is a back view of the cell, and FIG. 4 is a plan view of the cell. The front view and FIG. 5 are partial cross-sectional views showing a state in which the culture cells shown in FIGS. 1 to 4 are suspended in a multi-culture well plate to culture epithelial cells.
培養セル(1)の底部に設ける生体親和性高分子膜(2
)としては、培養細胞を良好に付着させ、その生存と増
殖を阻害せず、栄養成分や細胞代謝物等を適度番こ通過
させる摸を使用する。A biocompatible polymer membrane (2) provided at the bottom of the culture cell (1)
), use a model that allows cultured cells to adhere well, does not inhibit their survival and proliferation, and allows nutrients, cell metabolites, etc. to pass through to an appropriate level.
この種の嘆として1よ、生体親和性高分子から製膜して
得られるものをそのまま使用してもよく、あるいは常套
の嗅フィルター(2′)、例えば混合セルロースエステ
ノ呟ポリカーポ坏−ト、ポリエチレン−テレフタレート
、ポリスチレンまたは7ノ素樹脂等を材質とする精密濾
過膜、限外濾過膜または透析膜等を生体親和性高分子で
被覆したものを使用してもよい。但し、顕微鏡的観察を
必要とする場合には、水性溶媒中で透明な四フッ化エチ
レン樹脂、フン素樹脂と他の親水性高分子の共重体もし
くは7ノ素樹脂表面に生体親和性高分子を被覆した膜、
コラーゲンもしくはポリアミノ酸(ポリメチルグルタメ
ート、ポリリジン)から成る膜またはこれらの膜の表面
をプラズマ放電加工した膜が好適であ乙。As for this type of filter, 1) a film obtained by forming a film from a biocompatible polymer may be used as it is, or a conventional olfactory filter (2'), such as a mixed cellulose ester, polycarbonate, etc. A microfiltration membrane, an ultrafiltration membrane, or a dialysis membrane made of polyethylene terephthalate, polystyrene, or 7-carbon resin and coated with a biocompatible polymer may be used. However, if microscopic observation is required, transparent tetrafluoroethylene resin, a copolymer of fluorocarbon resin and other hydrophilic polymers, or a biocompatible polymer on the surface of 7-carbon resin may be used in an aqueous solvent. a membrane coated with
Membranes made of collagen or polyamino acids (polymethylglutamate, polylysine), or membranes whose surfaces have been subjected to plasma electrical discharge machining are suitable.
生体親和性高分子としては、コラーゲン(1型、■型、
■型、■型)、ファイプロネクチン、ラミニン、イガイ
(Mytilus edulis)の可溶化抽出物[例
えば、バイオ・ポリマーズ社の製品「セル・タフ(Ce
ll−Tak)コ等]、ポリ−D−りン゛ン、EHSマ
ウス腫瘍の可溶化抽出物[例えば、コラポレイティブ社
の製品[マトリゲル(Matrigel)J等]、ヒド
ロネクチンおよび血清中の細胞接着因子含有成分等が例
示されるが、特にコラーゲン■型及び■型と他型の複合
またはイガイ可溶化抽出物が好ましい。Biocompatible polymers include collagen (type 1, type ■,
Type ■, Type ■), phipronectin, laminin, solubilized extract of Mytilus edulis [e.g.
ll-Tak), etc.], poly-D-rin, solubilized extracts of EHS mouse tumors [e.g. Collaborative products [Matrigel J, etc.], hydronectin and cells in serum. Examples include adhesive factor-containing components, and particularly preferred are type 1 collagen, a composite of type 2 and other types of collagen, or a solubilized extract of mussel.
上記の生体親和性高分子を膜フィルターに被覆する態様
においては、生体親和性高分子を溶媒、例えば、培地、
水、緩衝液(例えば、ダルベツコのリン酸緩衝液、HE
PESJii衝液、Hanks’バランス塩溶液、Ea
rleのバランス塩溶液)または官製溶媒(例えば、エ
タノール等のアルコール、)に約0,01〜1%の濃度
で溶解させた溶液を膜フィルター上に塗布し、無菌的に
乾燥を行なった後、紫外線もしくは放射線を照射する。In an embodiment in which a membrane filter is coated with the above-mentioned biocompatible polymer, the biocompatible polymer is coated with a solvent, such as a medium,
water, buffers (e.g. Dulbecco's phosphate buffer, HE
PESJii solution, Hanks' balanced salt solution, Ea
A solution prepared by dissolving the membrane filter in a concentration of about 0.01 to 1% in a balanced salt solution of RLE) or an official solvent (e.g., alcohol such as ethanol) is applied onto the membrane filter, dried aseptically, and then Irradiate with ultraviolet light or radiation.
この場合、溶媒として培地を使用すると、細胞の増殖が
特に良好に行なわれる。In this case, the cells grow particularly well when a medium is used as the solvent.
上記の生体親和性膜(2)を底部に設けた培養セル(1
)はマルチ培養ウェルプレート(3)に懸垂され、該生
体親和性膜(2)の上に上皮細胞(4)が接種される。A culture cell (1) with the above-mentioned biocompatible membrane (2) provided at the bottom.
) is suspended in a multi-culture well plate (3), and epithelial cells (4) are inoculated onto the biocompatible membrane (2).
接種された上皮細胞(4)は、ヒト、マウス、ラット、
ハムスター、モルモット、ウサギ、イヌ、サノ呟ウシ、
ウマ、ブタ、ヒツジおよびヤギ等の動物に由来する初代
培養上皮細胞もしくは正常二倍体上皮細胞、例えば表皮
角化細胞、乳腺上皮細胞および角膜上皮細胞等から、薬
理試験の目的等に応じて適宜選定すればよい。The inoculated epithelial cells (4) are human, mouse, rat,
Hamsters, guinea pigs, rabbits, dogs, cows,
From primary cultured epithelial cells or normal diploid epithelial cells derived from animals such as horses, pigs, sheep, and goats, such as epidermal keratinocytes, mammary gland epithelial cells, and corneal epithelial cells, as appropriate depending on the purpose of pharmacological testing, etc. Just choose.
この種の上皮細胞は通常、接種前に次の前処理に付され
る:
ペニシリンやストレプトマイシン等の抗生物質の緩衝液
(pH約6.8〜7.2)を用いて殺菌される上皮細胞
は数m屑角の大きさに刻んだ後、コラゲナーゼ、ディス
パーゼ、ヒアルロニダーゼやトリプシン等の酵素を用い
組織を細胞ごとに切断し、約30〜37°Cにおいて約
5〜15分間保持した後、濾取し、次いで遠心分離処理
に付して得られる沈降細胞を水性媒体に再懸濁させる。These types of epithelial cells are usually subjected to the following pretreatment before inoculation: Epithelial cells are sterilized using a buffer (pH approximately 6.8-7.2) of antibiotics such as penicillin or streptomycin. After chopping into pieces several meters square in size, the tissue was cut into individual cells using enzymes such as collagenase, dispase, hyaluronidase, and trypsin, kept at about 30 to 37°C for about 5 to 15 minutes, and then filtered. Then, the sedimented cells obtained by centrifugation are resuspended in an aqueous medium.
培養セル(1)の生体親和性高分子膜(2)の上に接種
した上皮細胞の培養は、培養セルと培養ウェルとの間隙
に培地(5)を導入することによって行なう。培地(5
)はMCDB153[rグロウス・アンド・ディファレ
ンシェーション・オン・ママリー・エビセリアル・セル
ズ・イン・カルチャー(Growth andDiff
erentiation of Mammary Ep
ithelialCalls in Cu1ture)
J、ジャパン・サイエンティフッタ・ソサイアティーズ
・プレス、東京(1987年)、第72頁〜第73頁参
照]、インスリン、表皮細胞成長因子、ハイドロコーチ
ゾンおよびウシ下垂体抽出物を必須成分とし、通常、M
CDB153 1000dあたり、インスリン約1〜2
0ttti/rnQ、表皮細胞成長因子約1.−50
p g/m(1゜ハイドロコーチゾン約100〜100
0μg/dおよびウシ下垂体抽出物約to−100μg
/mQ含有する。The epithelial cells inoculated onto the biocompatible polymer membrane (2) of the culture cell (1) are cultured by introducing a medium (5) into the gap between the culture cell and the culture well. Medium (5
) is MCDB153
erentiation of Mammary Ep
itherialCalls in Culture)
J, Japan Scientific Societies Press, Tokyo (1987), pp. 72-73], insulin, epidermal growth factor, hydrocortisone and bovine pituitary extract as essential ingredients, Usually, M
About 1-2 insulin per 1000d of CDB153
0ttti/rnQ, epidermal growth factor approximately 1. -50
p g/m (1° Hydrocortisone approx. 100-100
0 μg/d and approximately to-100 μg of bovine pituitary extract
Contains /mQ.
上皮細胞(4)の培養温度および培養時間は所望の培養
上皮細胞の層の厚さ、上皮細胞の種類、上皮細胞の入手
源等に応じて適宜選定すればよく、特に限定的ではない
が、通常は約35〜39°Cにおいて約5〜20日間行
ない、これによって約2〜10層の培養上皮細胞が調製
される。The culture temperature and culture time of the epithelial cells (4) may be appropriately selected depending on the desired thickness of the cultured epithelial cell layer, the type of epithelial cells, the source of the epithelial cells, etc., and are not particularly limited. This is usually carried out at about 35 to 39°C for about 5 to 20 days, thereby preparing about 2 to 10 layers of cultured epithelial cells.
なお、上記の培養中においては、適当な時間、例えば2
4〜48時間毎に培養セル(+)内および培養セル(1
)と培養ウェル(3)との間隙内に存在する培地を新鮮
な培地と適宜交換するのが好ましい。It should be noted that during the above culture, an appropriate period of time, e.g. 2
Every 4 to 48 hours, culture cells (+) and culture cells (1
) and the culture well (3) is preferably replaced with fresh medium as appropriate.
また、上記の培養を行なった後、所望によりCa2+ま
たは血清等の分化誘導因子を培地に添加してさらに培養
を続行することによって細胞の分化を併発させ、分化細
胞に対する薬物試験用の試料を調製してもよい。After performing the above culture, if desired, a differentiation-inducing factor such as Ca2+ or serum is added to the medium and the culture is continued to induce cell differentiation, thereby preparing a sample for drug testing on differentiated cells. You may.
上記のようにしても調製される培養細胞は、生体上皮細
胞に近い層化細胞であり、種々の薬物試験において信頼
性の高いデータを提供する。The cultured cells prepared as described above are stratified cells similar to living epithelial cells, and provide highly reliable data in various drug tests.
本発明による多層培養上皮細胞は、例えば次の様な薬物
試験に使用することができる。The multilayer cultured epithelial cells according to the present invention can be used, for example, in the following drug tests.
毒性試験
第5図に示す容器に用いて培養した細胞を保をする培養
セル内に、培地に溶かした薬物を入れ、培養セルと培養
ウェルとの間に薬物不含培地を入れた後(培養セルと培
養ウェル内の培地の液面はほぼ等しくする)、インキュ
ベータを使用して、CO2を5%前後含含量る空気中に
おいて37℃で培養を所定時間待なう。培養後、生死細
胞の選択的染色を、例えばギムザ染色法等の常法によっ
て行ない、死細胞面積を観察により求めることによって
薬物の毒性を評価する。Toxicity test A drug dissolved in a medium is placed in a culture cell that holds cultured cells using the container shown in Figure 5, and a drug-free medium is placed between the culture cell and the culture well. (The liquid levels of the cells and the culture medium in the culture wells should be approximately equal), and using an incubator, wait for culture at 37° C. for a predetermined period of time in air containing about 5% CO2. After culturing, selective staining of live and dead cells is performed by a conventional method such as Giemsa staining, and the toxicity of the drug is evaluated by determining the area of dead cells by observation.
なお、薬物は培地に溶かさないで、細胞層上に直接載せ
てもよい。Note that the drug may be directly placed on the cell layer without being dissolved in the medium.
刺激性試験
上記の毒性試験と同一の方法によって培養を行なった後
、細胞の形態的変化を顕微鏡によって観察して薬物の刺
激性を評価する。Irritation test After culturing is performed in the same manner as in the toxicity test above, the morphological changes in the cells are observed under a microscope to evaluate the irritation of the drug.
細胞膜浸透性試験
第5図に示す培養細胞を保有する培養セルの内外に培地
を入れ、培養セル内にはさらに薬物または蛍光性物質も
しくは放射性物質で標識しt;薬物を入れた後、培養を
所定時間待ない、薬物とは反対側の細胞層へ浸透した成
分、例えば糖、アミノ酸、ステロイド、脂肪酸、無機イ
オン、ペプチド等を分析する。Cell membrane permeability test A culture medium is placed inside and outside the culture cell holding the cultured cells shown in Figure 5, and the culture cell is further labeled with a drug, a fluorescent substance, or a radioactive substance; after adding the drug, culture is started. After waiting for a predetermined period of time, components that have penetrated into the cell layer on the opposite side of the drug, such as sugars, amino acids, steroids, fatty acids, inorganic ions, and peptides, are analyzed.
なお、培養セルの外側のみに培地を入れ、薬物を培養セ
ル内の細胞層上に直接載せることによって上記試験を行
なってもよい。Note that the above test may be performed by placing the medium only on the outside of the culture cell and placing the drug directly on the cell layer inside the culture cell.
細胞内代謝性試験
上記の細胞膜浸透性試験の場合と同様にして培養を行な
い、細胞層の反対側に浸透した薬物の代謝物を分析する
。Intracellular metabolic test Culture is performed in the same manner as in the cell membrane permeability test described above, and metabolites of the drug that have permeated to the opposite side of the cell layer are analyzed.
以下、本発明を実施例によってさらに説明する。Hereinafter, the present invention will be further explained by examples.
実施例1
第1図〜第4図に示す培養セルの底部に設けたフッ素樹
脂製膜に、滅菌した3、0mg/mQの酸可溶性I型コ
ラーゲン1m(lと培地(MCDBI531000mQ
1インスリン3mg、表皮細胞成長因子5I119、ハ
イドロコーチゾン100g+9およびウシ下垂体抽出物
56mg)9+npとの混合液0 、2 mQを塗布し
、20℃で10時間乾燥した後、紫外線を20分間照射
した。塗膜を前記の培地0.2mQで3回洗浄した(1
58μg/cが)。Example 1 1 m (l) of sterilized acid-soluble type I collagen of 3.0 mg/mQ and a medium (MCDBI531000 mQ
0.2 mQ of a mixture of 1 insulin (3 mg), epidermal cell growth factor 5I (119), hydrocortisone (100 g +9) and bovine pituitary extract (56 mg)9 + np was applied, dried at 20°C for 10 hours, and then irradiated with ultraviolet light for 20 minutes. The coating film was washed three times with 0.2 mQ of the above medium (1
58 μg/c).
次いで、ヒトの表皮角化細胞(5,0XIO’細胞/r
aQ)をコラーゲン膜上1: 0 、2 rxQ接種し
、この培養セルを第5図に示すようにしてマルチ培養ウ
ェル内に懸垂させ、培養ウェル内に上記の培地0゜5蝦
入れ、培養を72時間行なった。この間、24時間毎に
、培養セルと培養ウェル内の培地を新鮮な培地と交換し
た。Next, human epidermal keratinocytes (5,0XIO' cells/r
aQ) was inoculated onto the collagen membrane at a ratio of 1:0, 2 rxQ, and the cultured cells were suspended in a multi-culture well as shown in Figure 5. The above medium 0.5 cm was placed in the culture well, and the culture was continued. It lasted 72 hours. During this period, the culture medium in the culture cells and culture wells was replaced with fresh medium every 24 hours.
得られた培養細胞層が均一な厚さを有することおよびピ
ンホールを有しないことは、顕微鏡観察において、同一
視野の細胞層の焦点距離が同時に合ったことおよび細胞
染色によって膜上の細胞全体が均一に染まったことによ
ってそれぞれ確認しtこ。The fact that the resulting cultured cell layer has a uniform thickness and no pinholes is due to the fact that the focal distances of the cell layers in the same field of view were aligned at the same time during microscopic observation, and the fact that the entire cell on the membrane was observed by cell staining. Confirm each color is evenly dyed.
また、培養細胞層のパラフィン薄片を常法によって作成
し、これを顕微鏡で観察したところ、細胞層は均一な3
層であった。In addition, paraffin thin sections of the cultured cell layer were prepared using a conventional method and observed under a microscope.
It was a layer.
実施例2
実施例)で使用した培養セルと同様の培養セル内には、
上記培地にラウリル硫酸ソーダを5 p[’410pp
m、25ppm、 50ppmまたはl OOppm
添加した培地を入れ、培養を24時間行なった後、培養
セル内の細胞層をトリバンブルーで染色し、染色した死
細胞面積を顕微鏡によって調べたところ、ラウリル硫酸
ソーダを5ppm、 l Oppmまたは25ppm
添加しI;培地を用いた場合には細胞の染色は認められ
なかったが、50ppmまたはl OOppm添加した
培地を用いた場合にはほぼすべての細胞が均一に染色し
、すべての細胞層が薬物に対して同等の感受性を示した
。Example 2 In a culture cell similar to the culture cell used in Example),
Add 5 p ['410 pp] of sodium lauryl sulfate to the above medium.
m, 25ppm, 50ppm or lOOppm
After adding the added medium and culturing for 24 hours, the cell layer in the culture cell was stained with Trivan blue, and the area of stained dead cells was examined using a microscope.
No staining of cells was observed when using a medium containing 50 ppm or 1 Oppm, but almost all cells were uniformly stained and all cell layers were stained with the drug. showed similar susceptibility to
発明の効果
本発明によって得られる多層培養上皮細胞は、厚さが均
一で、ピンホールを有さない生体上皮細胞に近似する層
化細胞であり、種々の薬物試験等に使用する場合には、
生体内の状態を正確に反映する信頼性の高いデータを提
供する。Effects of the Invention The multilayer cultured epithelial cells obtained by the present invention are stratified cells that have a uniform thickness and do not have pinholes and resemble biological epithelial cells, and when used in various drug tests, etc.
Provide highly reliable data that accurately reflects in-vivo conditions.
第1図は本発明を実施するのに好適な培養セルの一態様
を示す平面図、第2図は該セルの下面図、第3図は該セ
ルの背面図、第4図は該セルの正面図および第5図は第
1図〜第4図に示す培養セルをマルチ培養ウェルプレー
トに懸垂して上皮細胞を培養する状態を示す部分的断面
図である。
(1)は培養セル、(2)は生体親和性高分子膜、(2
″)は膜フイルタ−、(3)はマルチ培養ウェルプレー
ト、(4)は上皮細胞、(5)は培地を示す。
第1
図
第3図FIG. 1 is a plan view showing one embodiment of a culture cell suitable for carrying out the present invention, FIG. 2 is a bottom view of the cell, FIG. 3 is a rear view of the cell, and FIG. 4 is a top view of the cell. The front view and FIG. 5 are partial sectional views showing a state in which the culture cells shown in FIGS. 1 to 4 are suspended in a multi-culture well plate to culture epithelial cells. (1) is a culture cell, (2) is a biocompatible polymer membrane, (2)
'') indicates a membrane filter, (3) indicates a multi-culture well plate, (4) indicates epithelial cells, and (5) indicates a medium. Fig. 1 Fig. 3
Claims (1)
皮細胞を接種し、該上皮細胞を、MCDB153、イン
スリン、表皮細胞成長因子、ハイドロコーチゾンおよび
ウシ下垂体抽出物を含有する培地を用いて培養すること
を特徴とする多層培養上皮細胞の製法。 2、請求項1記載の製法によって得られる多層培養上皮
細胞。 3、請求項2記載の多層培養上皮細胞を使用する薬物試
験方法。[Claims] 1. Epithelial cells are inoculated onto a biocompatible polymer membrane provided at the bottom of a culture cell, and the epithelial cells are treated with MCDB153, insulin, epidermal growth factor, hydrocortisone, and bovine pituitary gland extract. 1. A method for producing multilayer cultured epithelial cells, which comprises culturing using a medium containing a substance. 2. Multilayer cultured epithelial cells obtained by the method according to claim 1. 3. A drug testing method using the multilayer cultured epithelial cells according to claim 2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63266579A JPH02113885A (en) | 1988-10-20 | 1988-10-20 | Preparation of epithelial cell cultured in multiple layers |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63266579A JPH02113885A (en) | 1988-10-20 | 1988-10-20 | Preparation of epithelial cell cultured in multiple layers |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH02113885A true JPH02113885A (en) | 1990-04-26 |
Family
ID=17432769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63266579A Pending JPH02113885A (en) | 1988-10-20 | 1988-10-20 | Preparation of epithelial cell cultured in multiple layers |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH02113885A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7601487B2 (en) | 2005-04-12 | 2009-10-13 | Cleo Cosmetic And Pharmaceutical Co., Llc | Composition using HMW dextran and method for in vitro preservation of corneal tissues |
-
1988
- 1988-10-20 JP JP63266579A patent/JPH02113885A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7601487B2 (en) | 2005-04-12 | 2009-10-13 | Cleo Cosmetic And Pharmaceutical Co., Llc | Composition using HMW dextran and method for in vitro preservation of corneal tissues |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0418035B1 (en) | Living tissue equivalents | |
EP2639293B1 (en) | Cell culture chamber, method for producing same, tissue model using cell culture chamber, and method for producing same | |
US8222031B2 (en) | Three-dimensional skin model | |
CN103356701B (en) | Pharmaceutical composition for cell therapy of pigmentation disorders | |
CN101352586B (en) | Method for preparing full-thickness skin for toxicity test by stem cell raft type cultivation | |
CN102051343A (en) | Bioengineered tissue constructs and methods for producing and using them | |
CN107849530A (en) | Blood vessel tissue, skin or mucous membrane equivalent | |
KR102426746B1 (en) | Method and system for regenerating hair using 3D organoid system of hair follicle stem cells | |
JPWO2005014774A1 (en) | Animal cell culture carrier, animal cell culture method and transplantation method using the culture carrier | |
JP2019514370A (en) | In vitro complete skin model containing three-dimensional cell culture model of sweat gland | |
WO2007090575A1 (en) | Skin model with dendritic cells | |
JP2001518621A (en) | Multicellular in vitro assay of angiogenesis | |
CN107683148A (en) | Skin renewal method | |
CN105353114A (en) | Melanin-containing in vitro skin test model and preparation method | |
CN109722410B (en) | 3D full-layer skin model, culture medium for forming same and preparation method | |
JPH02113885A (en) | Preparation of epithelial cell cultured in multiple layers | |
KR102113778B1 (en) | Myocardial-like structures prepared using porous supports method for evaluating drug toxicity using the same | |
CN111117945B (en) | Skin model containing melanin, construction method and application thereof | |
Penfornis et al. | Three-dimensional spheroid model using cancer and stromal cells for in vitro drug screening assays | |
RU2808599C1 (en) | Method of creating artificial equivalent of human round window membrane | |
Tres et al. | Permeable collagen-glycosaminoglycan cross-linked copolymers for the study of biological responses of coculturede Sertoli and spermatogenic cells | |
Sahle et al. | A Fibrin‐Based Human Multicellular Gingival 3D Model Provides Biomimicry and Enables Long‐Term In Vitro Studies | |
Piasek et al. | Building Up Skin Models for Numerous Applications-from Two-Dimensional (2D) Monoculture to Three-Dimensional (3D) Multiculture | |
CZ36189U1 (en) | Intestinal tissue model for toxicological testing and equipment for preparing it | |
JPH05336996A (en) | Method for testing cytotoxicity with cultured cell |